) --

Neurocrine Biosciences



) hit a new 52-week high Thursday as it is currently trading at $8.62, above its previous 52-week high of $8.60 with 64,263 shares traded as of 11:33 a.m. ET. Average volume has been 305,900 shares over the past 30 days.

Neurocrine has a market cap of $466.4 million and is part of the

health care

sector and


industry. Shares are up 10.5% year to date as of the close of trading on Wednesday.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company has a P/E ratio of 12.2, above the average drugs industry P/E ratio of 12.1 and below the S&P 500 P/E ratio of 17.7.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Neurocrine as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full

Neurocrine Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center